OtherArticle
Keratinocyte-derived VEGF biosynthesis represents a pleiotropic side effect of PPARγ agonist troglitazone but not rosiglitazone and involves activation of p38 MAPK: implications for diabetes-impaired skin repair
Dana Schiefelbein, Oliver Seitz, Itamar Goren, Jan Philipp DiBmann, Helmut Schmidt, Malte Bachmann, Robert Sader, Gerd Geisslinger, Josef Pfeilschifter and Stefan Frank
Molecular Pharmacology July 3, 2008, DOI: https://doi.org/10.1124/mol.108.049395
Dana Schiefelbein
Oliver Seitz
Itamar Goren
Jan Philipp DiBmann
Helmut Schmidt
Malte Bachmann
Robert Sader
Gerd Geisslinger
Josef Pfeilschifter
Jump to comment:
No eLetters have been published for this article.
In this issue
Molecular Pharmacology
Vol. 105, Issue 4
1 Apr 2024
OtherArticle
Keratinocyte-derived VEGF biosynthesis represents a pleiotropic side effect of PPARγ agonist troglitazone but not rosiglitazone and involves activation of p38 MAPK: implications for diabetes-impaired skin repair
Dana Schiefelbein, Oliver Seitz, Itamar Goren, Jan Philipp DiBmann, Helmut Schmidt, Malte Bachmann, Robert Sader, Gerd Geisslinger, Josef Pfeilschifter and Stefan Frank
Molecular Pharmacology July 3, 2008, DOI: https://doi.org/10.1124/mol.108.049395
OtherArticle
Keratinocyte-derived VEGF biosynthesis represents a pleiotropic side effect of PPARγ agonist troglitazone but not rosiglitazone and involves activation of p38 MAPK: implications for diabetes-impaired skin repair
Dana Schiefelbein, Oliver Seitz, Itamar Goren, Jan Philipp DiBmann, Helmut Schmidt, Malte Bachmann, Robert Sader, Gerd Geisslinger, Josef Pfeilschifter and Stefan Frank
Molecular Pharmacology July 3, 2008, DOI: https://doi.org/10.1124/mol.108.049395
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement